Introduction & Objective: Hospital discharge is a vulnerable period for persons with type 2 diabetes (T2D). We assessed the feasibility and efficacy of remote (RM) vs. manual (MM) monitoring using a continuous glucose monitor (CGM).

Methods: In this prospective cohort study, persons with T2D, A1c >8%, and basal insulin use received a Dexcom G6 following discharge. This analysis includes 14-day CGM reports at 4 weeks after discharge for the first 100 participants. Key outcomes were stratified by either RM vs MM of CGM data and include % time in range (70-180 mg/dl, TIR).

Results: Among the 100 participants, 52 were RM and 48 were MM. Barriers in the MM group included incompatible cell phone (48%), no smartphone (46%), or other (4.2%). The RM group was younger, more likely to be employed, and had higher numeracy compared to the MM group. CGM data were available at 4 weeks in 62% of RM vs 56% of MM, p=0.69, and time in use was >95% in both groups. Median glucose was 176 (IQR 143, 215) vs 203 (IQR 183, 248, p=0.02) mg/dL in the RM vs MM group. Median TIR was 53% (IQR 33, 82) vs 40% (IQR 20, 49, p=0.04) in the RM vs. MM group and % time <70 mg/dl was <1% for both groups.

Conclusion: Early findings suggest that CGM with RM is associated with higher TIR compared to CGM with manual downloads following hospitalization. Overcoming technological barriers to RM may improve glycemic outcomes post-discharge.

graphic
View largeDownload slide
Disclosure

S. Folk: None. T. Sobol: None. T. Gatti: None. C. Harris: None. E.R. Faulds: Advisory Panel; Dexcom, Inc. Research Support; Dexcom, Inc., Insulet Corporation. Other Relationship; A1Control. E. Buschur: Research Support; Dexcom, Inc. K. Wyne: None. P. Duncan: None. K.M. Dungan: Advisory Panel; Eli Lilly and Company, Dexcom, Inc. Research Support; Dexcom, Inc. Advisory Panel; Elsevier. Research Support; Abbott, ViaCyte, Inc., Sanofi, Omnipod. Advisory Panel; Omnipod. Other Relationship; Up-To-Date. Speaker's Bureau; Med Learning Group, Medscape, Cardiometabolic Health Congress. Consultant; Oppenheimer & Co. Speaker's Bureau; Integritas.

Funding

Dexcom

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.